京東健康(06618.HK)與泛生子達成癌症全週期管理戰略合作
京東健康(06618.HK)與癌症精準醫療公司泛生子(GTH.US)達成全面戰略合作,雙方將整合資源,發展癌症全週期管理互聯網創新模式。
首輪合作將聚焦肝癌和肺癌,依托泛生子肝癌早篩液體活檢產品HCCscreen、人類8基因突變聯合檢測試劑盒,與京東健康合作拓展癌症早篩、分子分型、用藥指導、耐藥監測等癌症全週期管理服務。
HCCscreen將於近期上線京東健康平台科普活動及「618」肝癌早篩專場活動,人類8基因突變聯合檢測試劑盒並將入駐京東健康互聯網醫院及線下藥店。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.